| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Martin A Katzma. Current considerations in the treatment of generalized anxiety disorder. CNS drugs. vol 23. issue 2. 2009-04-28. PMID:19173371. |
the consensus across current treatment guidelines is that first-line treatment for patients with gad should consist of an antidepressant, either a selective serotonin reuptake inhibitor (ssri) such as sertraline, paroxetine or escitalopram, or a selective serotonin noradrenaline (norepinephrine) reuptake inhibitor (snri) such as venlafaxine or duloxetine. |
2009-04-28 |
2023-08-12 |
Not clear |
| Tetsuya Ikeda, Yasushi Ishida, Rumi Naono, Ryuichiro Takeda, Hiroshi Abe, Tadashi Nakamura, Toshikazu Nishimor. Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain. Neuroscience research. vol 63. issue 1. 2009-04-20. PMID:18992286. |
therefore, two kinds of newer antidepressants whose functions have been more fully clarified were selected, milnacipran, a serotonin and noradrenaline reuptake inhibitor (snri) and paroxetine and fluvoxamine, which are selective serotonin reuptake inhibitors (ssris). |
2009-04-20 |
2023-08-12 |
rat |
| Sarah Durkin, Alison Prendergast, Andrew Harki. Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 8. 2009-04-15. PMID:18824064. |
in parallel mdma treatment resulted in significant regional depletions of 5-ht and its metabolite 5-hydroxyindoleacetic acid (5-hiaa) accompanied by a reduction in cortical [3h] paroxetine binding to nerve terminal 5-ht transporters. |
2009-04-15 |
2023-08-12 |
rat |
| Salvatore Gentile, Cesario Bellantuon. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. The Journal of clinical psychiatry. vol 70. issue 3. 2009-04-13. PMID:19254517. |
selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. |
2009-04-13 |
2023-08-12 |
Not clear |
| Kensuke Orito, Akihiko Morishima, Tetsuo Ogawa, Katsumasa Muneoka, Makiko Kuwagata, Jiro Takata, Kenichi Mishima, Michihiro Fujiwar. Characteristic behavioral anomalies in rats prenatally exposed to 5-bromo-2'-deoxyuridine. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. vol 27. issue 1. 2009-04-09. PMID:18834934. |
paroxetine, a selective serotonin reuptake inhibitor, also normalized the hyperactivity and the low anxiety-related behavior in the elevated plus maze. |
2009-04-09 |
2023-08-12 |
rat |
| Shannon Pearce, Nasiva Ahned, Grace M Vara. A case study of delayed serotonin syndrome: lessons learned. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. vol 24. issue 1. 2009-04-07. PMID:19275460. |
the initial working diagnosis did not include serotonin syndrome, but once other studies did not reveal an etiology of the symptoms and the patient continued to be delirious, paroxetine was discontinued and all symptoms resolved within 48 hours of last dose. |
2009-04-07 |
2023-08-12 |
Not clear |
| A Cupello, C Albano, E Gatta, S Scarrone, E Villa, G Zon. Binding of paroxetine to the serotonin transporter in membranes from different cells, subcellular fractions and species. Neurochemical research. vol 34. issue 2. 2009-03-30. PMID:18563559. |
binding of paroxetine to the serotonin transporter in membranes from different cells, subcellular fractions and species. |
2009-03-30 |
2023-08-12 |
human |
| Sonja Ständer, Barbara Böckenholt, Funda Schürmeyer-Horst, Carsten Weishaupt, Gereon Heuft, Thomas A Luger, Gudrun Schneide. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta dermato-venereologica. vol 89. issue 1. 2009-03-30. PMID:19197541. |
treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. |
2009-03-30 |
2023-08-12 |
Not clear |
| Henricus G Ruhé, Jan Booij, Henk C v Weert, Johannes B Reitsma, Eric J F Franssen, Eric J F Fransen, Martin C Michel, Aart H Schen. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 34. issue 4. 2009-03-23. PMID:18830236. |
evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. |
2009-03-23 |
2023-08-12 |
Not clear |
| Henricus G Ruhé, Jan Booij, Henk C v Weert, Johannes B Reitsma, Eric J F Franssen, Eric J F Fransen, Martin C Michel, Aart H Schen. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 34. issue 4. 2009-03-23. PMID:18830236. |
we aimed to reassess the efficacy of paroxetine dose escalation and quantify whether paroxetine dose escalation increases occupancy of the serotonin transporter (sert) more than placebo dose escalation in a randomized controlled trial. |
2009-03-23 |
2023-08-12 |
Not clear |
| Ivan Skelin, Fumitaka Yamane, Mirko Diksi. Flesinoxan challenge suggests that chronic treatment with paroxetine in rats does not desensitize receptors controlling 5-HT synthesis. Neurochemistry international. vol 53. issue 6-8. 2009-03-09. PMID:18786747. |
flesinoxan challenge suggests that chronic treatment with paroxetine in rats does not desensitize receptors controlling 5-ht synthesis. |
2009-03-09 |
2023-08-12 |
rat |
| Ivan Skelin, Fumitaka Yamane, Mirko Diksi. Flesinoxan challenge suggests that chronic treatment with paroxetine in rats does not desensitize receptors controlling 5-HT synthesis. Neurochemistry international. vol 53. issue 6-8. 2009-03-09. PMID:18786747. |
the main objective of this study was evaluation of ability of 5-ht(1a) receptors to modulate 5-ht synthesis after 14-day paroxetine treatment. |
2009-03-09 |
2023-08-12 |
rat |
| Ivan Skelin, Fumitaka Yamane, Mirko Diksi. Flesinoxan challenge suggests that chronic treatment with paroxetine in rats does not desensitize receptors controlling 5-HT synthesis. Neurochemistry international. vol 53. issue 6-8. 2009-03-09. PMID:18786747. |
5-ht(1a) receptor sensitivity following chronic administration of the ssri paroxetine was assessed by the ability of an acute challenge with the 5-ht(1a) agonist, flesinoxan, to modulate 5-ht synthesis in the rat brain. |
2009-03-09 |
2023-08-12 |
rat |
| Ivan Skelin, Fumitaka Yamane, Mirko Diksi. Flesinoxan challenge suggests that chronic treatment with paroxetine in rats does not desensitize receptors controlling 5-HT synthesis. Neurochemistry international. vol 53. issue 6-8. 2009-03-09. PMID:18786747. |
the results also suggest that the 5-ht receptors were not fully desensitized by paroxetine treatment, and that the stimulation of 5-ht(1a) receptors with an agonist is still capable of reducing 5-ht synthesis. |
2009-03-09 |
2023-08-12 |
rat |
| E Anne MacGrego. Headache and hormone replacement therapy in the postmenopausal woman. Current treatment options in neurology. vol 11. issue 1. 2009-03-09. PMID:19094831. |
for women who have contraindications to estrogen therapy or do not wish to use it, compounds that inhibit serotonin reuptake, such as venlafaxine, fluoxetine, and paroxetine, have all shown efficacy for the control of hot flashes and prevention of migraine. |
2009-03-09 |
2023-08-12 |
Not clear |
| Henricus G Ruhé, Wendy Ooteman, Jan Booij, Martin C Michel, Martina Moeton, Frank Baas, Aart H Schen. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenetics and genomics. vol 19. issue 1. 2009-03-03. PMID:18987562. |
serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. |
2009-03-03 |
2023-08-12 |
Not clear |
| Michael J Owens, Stan Krulewicz, Jeffrey S Simon, David V Sheehan, Michael E Thase, David J Carpenter, Susan J Plott, Charles B Nemerof. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 13. 2009-02-19. PMID:18418363. |
estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. |
2009-02-19 |
2023-08-12 |
human |
| Michael J Owens, Stan Krulewicz, Jeffrey S Simon, David V Sheehan, Michael E Thase, David J Carpenter, Susan J Plott, Charles B Nemerof. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 13. 2009-02-19. PMID:18418363. |
paroxetine and venlafaxine are potent serotonin transporter (sert) antagonists and weaker norepinephrine transporter (net) antagonists. |
2009-02-19 |
2023-08-12 |
human |
| Michal Reichenstein, Moshe Rehavi, Albert Pinhaso. Involvement of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors in the mechanism of antidepressant action. Journal of molecular neuroscience : MN. vol 36. issue 1-3. 2009-02-17. PMID:18592413. |
in rat hippocampal neurons, prolonged (72-hour) treatment with selective serotonin reuptake inhibitors paroxetine and citalopram significantly up-regulated bdnf and pacap expression and down-regulated pacap receptor (pac1 and vpac2) expression; the tricyclic antidepressant imipramine had an opposite effect. |
2009-02-17 |
2023-08-12 |
rat |
| M V Schmidt, M Czisch, V Sterlemann, C Reinel, P Sämann, M B Mülle. Chronic social stress during adolescence in mice alters fat distribution in late life: prevention by antidepressant treatment. Stress (Amsterdam, Netherlands). vol 12. issue 1. 2009-02-13. PMID:18951248. |
further, we demonstrated that treatment with a selective serotonin reuptake inhibitor (paroxetine) during stress exposure prevented later effects on body fat distribution. |
2009-02-13 |
2023-08-12 |
mouse |